slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,471
Current window 100,321-100,350
Pages 3,950
Rows per page 30
Component
100,321-100,350 of 118,471
25
The slide uses a consistent color scheme where the most recent quarter (3Q23) is highlighted in a darker blue.FGI Industries | Investor Presentation Deck | 30 slides · FGI Industries
Pitch deck Investor relations Beat · Financials1 hit
01
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
10
The slide outlines the methodology and validation of a clinical trial.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
16
The slide outlines a clinical trial protocol for Olvi-Vec in ovarian cancer.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
18
Includes specific patient case reports (Pt #21A-06 and Pt #21A-04) showing tumor response metrics.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
20
The slide highlights the strategic partnership and the division of commercial rights between Genelux and Newsoara.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
21
The slide highlights the synergy between two distinct therapeutic approaches (oncolytic immunotherapy and adoptive cell therapy).Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
24
The slide categorizes the library into therapeutic genes, immune modularity, and therapeutic antibodies.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
32
The slide uses two distinct chart types to show longitudinal dynamics (line chart) and best response (waterfall chart) for the CA-125 biomarker.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
35
The slide uses histology images and HALO infiltration histograms to demonstrate the mechanism of action and clinical efficacy.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
36
The slide uses a combination of immunological data (ELISPOT) and clinical imaging data (SLD) to show causality between immune response and tumor shrinkage.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
05
The slide uses a combination of summary text, callouts for specific financial impacts, and detailed tables for per-day sales and organic growth metrics.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
15
Includes detailed line-item adjustments (A-J) with corresponding commentary.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
16
Includes footnotes A and B explaining specific adjustments.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
08
The slide uses a structural diagram to highlight the substitution of the 'Tumor Binding Domain' with the 'COBRA Binder' in the NXC-201 molecule.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
10
The slide uses external citations from Nature Medicine and Signal Transduction and Targeted Therapy to validate the scientific approach of ITAM modification.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
22
The slide uses a table structure to contrast patient segments and includes a bar chart visualization for patient growth.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
30
The slide uses a stylized area chart to represent market segments and their respective valuations.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
36
Includes a complex biological pathway diagram and three supporting charts (penetration depth, accumulation over time, and apoptosis efficacy).Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
39
The slide uses a comparative layout to position NXC-201 as a superior, one-time monotherapy against current multi-drug, weekly treatment regimens.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
48
Includes a process flow diagram illustrating the mechanism of action of iMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
54
Includes comparative size illustration of IMX-111 vs IgG antibody, and survival curve data.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
56
The slide uses a mix of mechanism-of-action diagrams, clinical trial bar charts, and preclinical mouse model data to validate the therapeutic approach.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
59
The slide uses a process-flow style layout to connect platform capabilities to specific product outputs.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
06
Innovid | Investor Day Presentation Deck | 74 slidesInnovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations Beat · Team1 hit
08
The slide uses a stylized global network map background to emphasize global reach.Innovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations Loop · Golden Circle1 hit
12
Innovid | Investor Day Presentation Deck | 74 slidesInnovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations 1 hit
35
Innovid | Investor Day Presentation Deck | 74 slidesInnovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations 1 hit
44
The chart illustrates the diversification of revenue away from a single product (Product 1) toward newer products (Product 2 and 3) over time.Innovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations 1 hit
48
The slide uses a comparison structure to link client needs (RFP drivers) to the vendor's value proposition (Why We Won).Innovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations 1 hit